Reshma L Mahtani (Reshma Mahtani)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 15

Top Topics

Tyrosine Kinase

Epidermal Growth Factor Receptor

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Current treatment options in oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma L Mahtani, Cynthia X Ma, Angela M DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara G Abdou, Elizabeth C Riley, Rubina Qamar, Priyanka Sharma, Sonya A Reid, Natalie Sinclair, Meredith Faggen, Caroline C Block, Naomi Y Ko, Ann H Partridge, Wendy Y Chen, Michelle DeMeo, Victoria Attaya, Amanda Okpoebo, Jillian Alberti, Yuan Liu, Eric Gauthier, Harold J Burstein, Meredith M Regan, Sara M Tolaney
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma L Mahtani, Cynthia X Ma, Angela M DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara G Abdou, Elizabeth C Riley, Rubina Qamar, Priyanka Sharma, Sonya A Reid, Natalie Sinclair, Meredith Faggen, Caroline C Block, Naomi Y Ko, Ann H Partridge, Wendy Y Chen, Michelle DeMeo, Victoria Attaya, Amanda Okpoebo, Jillian Alberti, Yuan Liu, Eric Gauthier, Harold J Burstein, Meredith M Regan, Sara M Tolaney
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (17) (2024)
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma L Mahtani, Cynthia X Ma, Angela M DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara G Abdou, Elizabeth C Riley, Rubina Qamar, Priyanka Sharma, Sonya A Reid, Natalie Sinclair, Meredith Faggen, Caroline C Block, Naomi Y Ko, Ann H Partridge, Wendy Y Chen, Michelle DeMeo, Victoria Attaya, Amanda Okpoebo, Jillian Alberti, Yuan Liu, Eric Gauthier, Harold J Burstein, Meredith M Regan, Sara M Tolaney
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (17) (2024)
Kristin M Zimmerman Savill, Jasmina Ivanova, Parisa Asgarisabet, Angelica Falkenstein, Alexandrina Balanean, Alexander Niyazov, Joanne C Ryan, Jonathan Kish, Ajeet Gajra, Reshma L Mahtani
Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer. The oncologist (2023)
Naomi Dempsey, Ana Sandoval, Reshma L Mahtani
Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy? Current treatment options in oncology (2023)
Reshma L Mahtani, Rajesh Belani, Jeffrey Crawford, David Dale, Lucy DeCosta, Prasad L Gawade, Chanh Huynh, Tatiana Lawrence, Sandra Lewis, William W MacLaughlin, Mohit Narang, Robert Rifkin
A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 30 (7) (2022)
Bolivar Arboleda-Osorio, Rupert Bartsch, Evandro de Azambuja, Erika Paige Hamilton, Nadia Harbeck, Jennifer R Klemp, Michael Knauer, Sherko Kuemmel, Reshma L Mahtani, Florian Scotté, Cynthia Villarreal Garza, Antonio Wolff
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel. The oncologist 27 (9) (2022)
Reshma L Mahtani, Alexander Niyazov, Katie Lewis, Alex Rider, Lucy Massey, Bhakti Arondekar, Michael P Lux
Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel. Advances in therapy (2022)
Reshma L Mahtani, Alexander Niyazov, Bhakti Arondekar, Katie Lewis, Alex Rider, Lucy Massey, Michael Patrick Lux
Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel. BMC cancer 22 (1) (2022)
Reshma L Mahtani, Alexander Niyazov, Bhakti Arondekar, Katie Lewis, Alex Rider, Lucy Massey, Michael Patrick Lux
Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel. BMC cancer 22 (1) (2022)
Reshma L Mahtani, Alexander Niyazov, Bhakti Arondekar, Katie Lewis, Alex Rider, Lucy Massey, Michael Patrick Lux
Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel. BMC cancer 22 (1) (2022)
Reshma L Mahtani, Jeffrey Crawford, Sinéad M Flannery, Tatiana Lawrence, Jennifer Schenfeld, Prasad L Gawade
Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety. BMC cancer 21 (1) (2021)
Bryan Paul Schneider, Guanglong Jiang, Tarah Jean Ballinger, Fei Shen, Christopher Chitambar, Rita Nanda, Carla Falkson, Filipa C Lynce, Christopher M Gallagher, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Karen Daily, Reshma L Mahtani, Michael A Thompson, Robert Graham, Maureen E Cooper, Dean C Pavlick, Lee A Albacker, Jeffrey Gregg, Jeffrey P Solzak, Yu-Hsiang Chen, Casey L Bales, Erica L Cantor, Bradley A Hancock, Nawal Kassem, Paul Helft, Bert O'Neil, Anna Maria V Storniolo, Sunil S Badve, Kathy D Miller, Milan Radovich
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (4) (2021)
Arturo Loaiza-Bonilla, Al Bowen Benson, Axel Grothey, Misagh Karimi, Samuel J Klempner, Daniel Lin, Reshma L Mahtani, Heloisa P Soares
Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. The oncologist 26 (8) (2021)
Jame Abraham, Robert Coleman, Anthony Elias, Frankie Ann Holmes, Kevin Kalinsky, Muaiad Kittaneh, Elyse Lower, Reshma L Mahtani, E Terry Mamounas, Mark Pegram, Charles Vogel, null null
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast cancer research and treatment 171 (1) (2018)